Posts Tagged by Boston

MIT Convergence Report, Video Now Available Online

Convergence Report ImageAnharris | Harris Communications Group

A landmark MIT Convergence report entitled “Convergence: The Future of Human Health”– released on June 23, 2016– and a video of launch proceedings are now available online.

The Convergence report and  related materials may be downloaded from  http://www.convergencerevolution.net/ . The launch proceedings,  held  on June 24 at the National Academy of Sciences in Washington, DC, are available at  https://vimeo.com/album/4020692 .

The  Convergence report, chaired by former MIT President Susan Hochfield, Nobel Laureate Philip Sharp and Koch Institute Director Tyler Jacks, outlines progress and challenges regarding Convergence science since the group’s 2011 report, “Convergence, The Third Revolution.”  The new report defines Convergence as “the merging of approaches and insights from historically distinct disciplines such as engineering, physics, computer science, chemistry, mathematics, and the life sciences” to  transform biomedicine and human health.

It argues  that bringing  Convergence to fruition requires strategic and sustained support from government, industry and academe.

images-1Anharris | Harris Communications Group

It is  is  available for download at: http://www.convergencerevolution.net/, along with other materials on Convergence issues.

The Convergence report draws on insights from several dozen expert participants at two workshops, as well as on input from scientists and researchers across academia, industry, and government. Their efforts have produced a wide range of recommendations for advancing convergence research, but the report emphasizes one critical barrier above all: the shortage of federal funding for convergence fields.

“Convergence science has advanced across many fronts, from nanotechnology to regenerative tissue,” says Sharp. “Although the promise has been recognized, the funding allocated for convergence research in biomedical science is small and needs to be expanded. In fact, there is no federal agency with the responsibility to fund convergence in biomedical research.”

National Insitutes of Health

National Institutes of Health

The National Institutes of Health (NIH) are the primary source of research funding for biomedical science in the United States. In 2015, only 3 percent of all principal investigators funded by NIH were from departments of engineering, bioengineering, physics, biophysics, or mathematics. Accordingly, the report’s authors call for increasing NIH funding for convergence research to at least 20 percent of the agency’s budget.

A video of the launch proceedings at the National Academies  is available at https://vimeo.com/album/4020692 .

Harris Communications Group’s Anita Harris and Linda Grace-Kobas are pleased to have worked on the writing and editing of the report; we’re looking forward to viewing the videos–and will report back when we’ve done so! In the meantime, we hope you’ll take a look.

–Anita M. Harris, Managing Director, Harris Communications Group

The Harris Communications Group is an award-winning public relations and marketing firm specializing in outreach for health, science and technology, worldwide. Located in Kendall Square, Cambridge, we’re on the pulse of some of the most exciting ideas, technologies and companies anywhere. 

 

 

HarrisCom Group Consults on MIT Convergence Report, 2016

MIT Dome

MIT Dome

Anita Harris and Linda Grace Kobas of the Harris Communications Group played key roles in the writing and editing of “Convergence: the Future of Health,” a report released today by the Massachusetts Institute of Technology (MIT).

The Convergence report is  aimed at accelerating a  “Convergence Revolution,” in which the tools, technologies, methods and insights of physical sciences, information technology and engineering are increasingly being employed in the life sciences to transform biomedicine, promising to enhance human health and well-being.

The Convergence report was chaired by Susan Hochfield,   former president of MIT and a neuroscientist; Tyler Jacks, Director of the David H. Koch Institute for Integrative Cancer Research at MIT; and Nobel Prize Laureate Phillip Sharp,  Institute Professor at MIT.

“It was a privilege to work with such a brilliant team on a project that holds the potential to transform biomedicine  in the US,” Harris said.

[media-credit standalone=0 name="NIH" align="alignright" width="187"]Brain image [/media-credit]

Brain image

The Convergence report draws on insights from several dozen expert participants at two workshops, as well as input from scientists and researchers across academia, industry, and government.  It includes a wide range of recommendations for advancing convergence research, but emphasizes one critical barrier above all: the shortage of federal funding for convergence fields.

As Sharp explained, “Convergence science has advanced across many fronts, from nanotechnology to regenerative tissue. Although the promise has been recognized, the funding allocated for convergence research in biomedical science is small and needs to be expanded. In fact, there is no federal agency with the responsibility to fund convergence in biomedical research.”

The National Institutes of Health (NIH) are the primary source of research funding for biomedical science in the United States. In 2015, only 3 percent of all principal investigators funded by NIH were from departments of engineering, bioengineering, physics, biophysics, or mathematics. Accordingly, the report  calls for increasing NIH funding for Convergence research to at least 20 percent of the agency’s budget.

Harris, aided by MIT graduate and post doctoral students, wrote the sections covering education and policy; a second author,  Al Hammond, a former editor at Science Magazine, wrote the scientific and technical sections.  Linda Grace-Kobas, former Cornell University News Director and a member of the Harris Communications Group, served as copy editor.  Kate Stoll of the MIT Washington office was the project manager.

dnaNIH

A forum on “Convergence: the Future of Health” will be held at the National Academies of Sciences, Engineering and Medicine in Washington, DC,  on Friday, June 24.

The report is available at http://www.convergencerevolution.net/2016-report .

The Harris Communications Group is an award-winning PR and marketing firm based in Cambridge, MA. Managing Director Anita M. Harris is a former journalist who covered health, science and technology for the MacNeil/Lehrer Report (now the NewsHour) of PBS. Linda Grace Kobas, also a former science journalist, served for many years as the Cornell University News Director

 

NuGEN Webinar: Sample Prep for NGS Cancer Detection in 500+ Gene Targets

Available on demand until March 22, 2016

SAN CARLOS, Calif.–(BUSINESS WIRE)–NuGEN Technologies is pleased to present a Webinar featuring the company’s newly launched Ovation Cancer Panel 2.0 Target Enrichment System–a sample preparation technology that allows NGS (next generation sequencing) detection of multiple changes in more than 500 individual genes implicated in cancer– from a single sample preparation.

Released in August, the new reagent kit updates NuGEN’s well-established Ovation Cancer Panel Target Enrichment System. It enables comprehensive and efficient NGS analysis of cancer samples in a single workflow by both (1) enriching for an improved and larger selection of cancer-related genes and (2) enabling the detection of gene-level copy number variations in addition to SNPs, mutations and indels. The new method can be used with either fresh or FFPE tissue sections to deliver sensitive and reproducible targeted genomic analysis. It can also be rapidly customized to provide target enrichment kits for any gene sets defined by the researcher within a target size range that may include thousands of genes or just a few.

Typically, to analyze single nucleotide mutations and copy number changes in a sample, researchers have had to employ completely different analysis of both types of changes. NuGEN’s new method allows simultaneous targeted analysis of both types of changes, from a single sample preparation, on a choice of Illumina NGS systems. It thus allows more comprehensive and efficient analysis of cancer samples.

The Webinar, which originally aired on September 22, 2015, is moderated by John Sterling, managing editor of Genetic Engineering and Biotechnology News. It features presentations by Luke Sherlin, PhD, NuGEN’s Director of Technical Support, and Stephanie Huelga, PhD, NuGEN’s Lead Bioinformatics Scientist. The speakers present data from target-enrichment studies with a 509 cancer gene panel using a simple protocol that generates sequence-ready libraries from good quality DNA as well as DNA derived from formalin-fixed paraffin-embedded (FFPE) tissues. The Webinar also includes a question and answer session with participating scientists.

The Ovation Cancer Panel 2.0 Target Enrichment System is the latest release in the company’s drive to offer tools for targeted resequencing that provide basic and clinical researchers with a holistic view of the underlying molecular biology of disease.

The Webinar will be available on the website of Genetic Engineering and Biotechnology News free of charge until March 22, 2016. To log on, please click here.

About NuGEN

NuGEN Technologies Inc. is a rapidly-growing, privately-held company providing innovative products and systems for the preparation of biologic samples for targeted genomic analysis. Founded in 2000 and based in San Carlos, CA, NuGEN has long been at the cutting edge of genomic technology, with accurate, cost-effective reagent kits for even the most challenging sample types. NuGEN products are used in more than 1000 leading life science institutes and in diagnostic and pharmaceutical companies in 40 countries.

The Harris Communications Group is an award-winning life science PR firm in Boston.

Welcome to the Harriscom Blog

Anita Harris photoHi, and welcome to HarrisCom blog–a publication of the Harris Communications Group of Cambridge, MA.
We’re an award-winning strategic communications firm specializing in integrated public relations, marketing communications and thought leadership for companies and organizations  in health, science, technology and energy fields.
The Harris Communications Group blog covers traditional and digital communications issues;  events;  cool companies, and  news of our clients.
We hope you’ll join the conversation through guest blogs or comments–and that you’ll subscribe and share our material with anyone you think would like to have it.
Anita Harris, President
Harris Communications Group
Cambridge, MA

Life Science PR: NuGEN launches sample prep kit for NGS analysis of multiple gene changes

Optimized for analysis of SNPs, mutations and copy number changes in 500+ cancer gene targets

Rapidly customizable for discovery, validation and highly-targeted clinical diagnostic testing in a single assay

NuGEN Technologies, of San Carlos, CA, today launched a sample preparation product that allows NGS detection of multiple changes in more than 500 individual genes implicated in cancer.

The reagent kit, based on NuGEN’s Single Primer Enrichment Technology (SPET), is called the Ovation Cancer Panel 2.0 Target Enrichment System. The new kit updates NuGEN’s well-established Ovation Cancer Panel Target Enrichment System both by enriching for an improved and larger selection of cancer-related genes, and by enabling the detection of gene level copy-number variations (CNV) in addition to SNPs, mutations and indels, in a single workflow. It can be used with either fresh or FFPE tissue sections to deliver sensitive and reproducible targeted genomic analysis.

The method can also be rapidly customized to provide target enrichment kits for any gene sets defined by the researcher within a target size range that may include thousands of genes or just a few.

The new product is the latest release in the company’s drive to offer tools for targeted resequencing that provide basic and clinical researchers with a holistic view of the underlying molecular biology of disease.

“We’re excited by this latest product introduction,” said NuGEN CEO Elizabeth Hutt. “The Ovation Cancer Panel 2.0 Target Enrichment System enables a more comprehensive picture of the biology of a particular sample. And by making it possible to analyze mutations, SNPs and gene copy number changes in a single assay, the new system will save researchers time and money and allow more efficient use of samples.”

Typically, to analyze single nucleotide mutations and copy number changes in a sample, researchers have had to employ completely different analysis platforms. NuGEN’s new method allows simultaneous targeted analysis of both types of changes, from a single sample preparation, on a choice of Illumina NGS systems.

According to Robert P. Sebra, Ph.D., Director of Technology Development at the Icahn Institute and Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai in New York: “The underlying cause of cancer involves critical alterations in the genome. These alterations may include point mutations, changes in gene copy number, combinations of these, and other genomic changes. Having a common NGS workflow to simultaneously detect multiple types of variations would be invaluable because it would conserve precious patient samples and offers the ability to reproduce or validate results.”

Hutt added: “For cancer research, combined mutation and CNV analysis is a valuable complement to NuGEN’s recently released Ovation Fusion Panel Target Enrichment System, which also uses SPET to detect both known and unknown gene fusions in all exons of a 500 gene panel.”

About NuGEN

NuGEN Technologies Inc. is a rapidly-growing, privately-held company providing innovative products and systems for the preparation of biologic samples for targeted genomic analysis. Founded in 2000 and based in San Carlos, CA, NuGEN has long been at the cutting edge of genomic technology, with accurate, cost-effective reagent kits for even the most challenging sample types. NuGEN products are used in more than 1000 leading life science institutes and in diagnostic and pharmaceutical companies in 40 countries.

About HarrisCom:
The Harris Communications Group is an award-winning PR and digital marketing firm based in Cambridge, MA. 

Life Science PR: 3 Companies Validate NGS Sample Prep Workflow

MULTI-SITE STUDY VALIDATES END-TO-END RNA-SEQ SAMPLE PREP WORKFLOW FOR HUMAN WHOLE BLOOD CLINICAL SAMPLES
System integrates PreAnalytiX GmbH and NuGEN Technologies innovations to ensure reliable, reproducible, cost-effective RNA-Sequencing analysis. Corporate study alliance model critical to standardization, bringing genomics to the clinic.

San Carlos, CA and Piscataway, NJ, July 15, 2015— A multi-site study has clinically validated an end-to-end workflow for the collection, storage, transport and preparation of human whole blood samples for RNA-Sequencing (RNA-Seq). The study, initiated in January 2015, integrated products from PreAnalytiX GmbH and NuGEN Technologies, which worked collaboratively with RUCDR Infinite Biologics at Rutgers University to measure the system’s efficacy for transcriptome profiling with clinical samples.

“We have determined that the PreAnalytiX/NuGEN integrated workflow ensures reproducible, accurate and sensitive results in RNA-Seq of whole blood. Importantly, this integrated workflow enables gene expression from total RNA, allowing researchers to study both protein coding and regulatory transcripts from human whole blood,” said Dr. Andrew Brooks, Chief Operating Officer of RUCDR Infinite Biologics, who led the study. Brooks is also an associate professor of Genetics at Rutgers University and directs the Bionomics Research and Technology Center at the Environmental and Occupational Health Science Institute there.  Brooks will outline the study results on Tuesday, July 14 at the  International Leaders in Biobanking Conference, in Toronto.

“This study is critical for clinical researchers because it demonstrates that by using the combined PreAnalytiX and NuGEN workflow, scientists in laboratories around the world can confidently share not only their data but also their samples,” Brooks said.  “And, by joining forces to validate the combination of their proprietary technologies, PreAnalytiX and NuGEN have taken the lead with RUCDR to deliver the standardization needed for broader adoption of genomics in the clinic.”

Brooks explained that total RNA derived from patient blood samples is used for a myriad of clinical genomics applications—such as discovery and analysis of disease-related biomarkers, identification of new therapeutic targets and monitoring disease progression and treatment. But there are factors that present challenges to data integrity when using whole blood. Collection, storage, purification, handling and transport methods may vary. Nucleic acids can degrade during handling and processing, resulting in unreliable results and bias in transcript abundance. Whole blood also contains high levels of uninformative ribosomal RNA and reticulocyte globin RNA, which can reduce sequencing efficiencies and increase costs.  Moreover, variation between sites and operators makes it difficult to standardize results among researchers and laboratories. “If researchers across multiple sites obtain different results, we need to be sure the variations are attributable to changes in the biology and not the technology,” he said.

At the Biobanking Congress, Brooks reported tight correlation in results across three sites in New Jersey with multiple operators, using several nanograms of total RNA from each of 10 subjects. That is, using PreAnalytiX technology for extraction, storage and transportation of samples and NuGEN technology for library formation and depletion of ribosomal RNA and globin prior to whole transcriptome analysis, the study team found high reproducibility of results across sites, operators and equipment. “The combined workflow led to reproducible whole blood collection and storage; reproducible and robust RNA extraction; reproducible and consistent library creation; and tight performance correlations across and within sites,” he said.

“This integrated sample prep workflow will be important for scientists seeking new genetic biomarkers for disease. It will be valuable to pharmaceutical clinical trials for determining if a therapeutic leads to genetic changes in a particular cancer. And it is  important to the future of clinical research because it allows the development of guidelines and standards for scientists who want to share samples, not just data, globally, across sites and experiments,” Brooks said.  “Without such standardization, many results might never advance to the clinic.”

The study used the PreanalytiX  PAXgene Blood RNA System for whole blood collection, storage and RNA extraction and NuGEN’s Insert Dependent Adaptor Cleavage (InDA-C) technology from the NuGEN Ovation Human Blood RNA-Seq System  to prepare strand-specific RNA-Seq libraries and for ribosomal/globin depletion. RUCDR Infinite Biologics oversaw sample collection, processing and data analysis.

About NuGEN

NuGEN Technologies is the leader in providing solutions which make biological samples accessible for genomic analysis, enabling scientists to capture the truest biology achievable, independent of the quantity or quality of the samples. The company has commercialized numerous proprietary DNA and RNA sample preparation products for use in research and diagnostic applications. Founded in 2000, NuGEN Technologies, Inc. is privately held and headquartered in San Carlos, CA. For more information please visit www.nugen.com

About RUCDR Infinite Biologics

RUCDR offers a complete and integrated selection of biological sample processing, analysis and biorepository services to government agencies, academic institutions, foundations and biotechnology and pharmaceutical companies within the global scientific community. RUCDR provides DNA, RNA and cell lines with clinical data to hundreds of research laboratories for studies on mental health and developmental disorders, drug and alcohol abuse, diabetes and digestive, liver and kidney diseases. RUCDR completed an $11.8 million expansion and renovation of its facilities in May 2013. Read more at www.rucdr.org

NuGEN and Ovation are registered trademarks of NuGEN Technologies, Inc.. PreAnalytiX and PAXgene are registered trademarks of PreAnalytiX GmbH.

The Harris Communications Group is an award-winning Life Science PR and thought leadership firm based in Cambridge, MA. 

u

Life Science PR: NuGEN on fusion detection

Pleased that  HarrisCom  life science PR client, NuGEN Technologies, has published an article in the journal PLOS ONE on a technology that allows scientists to use targeted next generation sequencing to screen for fusion events–gene abnormalities related to certain cancers.  They believe their new method  could help accelerate cancer research and development of treatments and diagnostic tests.   Here’s the press release: 

San Carlos, June   Scientists at NuGEN Technologies, Inc. have simultaneously surveyed RNA of more than 400 targeted genes in a single assay,  using next generation sequencing (NGS) to  detect fusions known to be key drivers of tumor growth in several cancer types. The scientists, who employed an innovative method of targeted sequence library preparation, also discovered low-frequency fusions that had not previously been reported.

The new method, which allows the simultaneous interrogation of multiple, specific genes for RNA sequencing, significantly simplifies fusion detection when compared with standard RNA sequencing approaches.

Based on NuGEN’s Single Primer Enrichment Technology (SPET), the method  “can greatly enhance scientists’ ability to understand the underlying oncogenic impact of a variety of genomic disruptions,” according to Elizabeth Hutt, the NuGEN CEO. “Applications based on this exciting new technology promise to speed up cancer research and lead to more effective diagnoses and treatments.”

As described in the June 1, 2015 issue of the peer-reviewed journal PLOS One, the scientists used the new method to prepare cancerous and normal tissue samples for targeted RNA sequencing.  The goal was to detect the presence of genes that had joined together or “fused”—resulting in disruption of regulatory mechanisms.  Through NGS, the scientists were able to identify multiple known and previously unreported fusions from fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tissue.
By targeting specific RNAs for sequencing, the scientists report, they were able to reduce the number of sequencing reads and increase the sensitivity of gene fusion detection, when compared with standard RNA-Seq methods.

“Traditional methods require a much larger number of sequencing reads in order to detect fusion events in a background of some 20,000 transcripts,” said Douglas Amorese, NuGEN Vice President of Research and Development. “Other focused methods cannot survey the entire repertoire of previously recognized fusions; they are limited to detection of small numbers of potential events.”

Additionally, the scientists write in PLOS, “The SPET-based assay is easy to use, has low RNA input requirements and can be used with RNA from formalin fixed, paraffin embedded (FFPE) tissue, which is important for clinically relevant samples. “ The assay is fully customizable to target any gene or set of genes in any genome.”

The new technology is one in a suite of sample preparation products NuGEN continues to develop in light of new scientific understanding about the shared molecular mechanisms underlying cancers originating in different tissues, according to Amorese.  While a tumor might appear to originate in a specific organ, the molecular mechanism or change involved may also play a role in cancers originating elsewhere.  (For example, certain breast and ovarian cancers exhibit similar genetic disruptions). This means that therapeutics effective in treating one type of tumor may also be useful in treating other tumors exhibiting similar molecular changes.

“Our technology allows researchers to better understand the cellular pathways that are disrupted,” Amorese said.

NuGEN’s new technology, offered in easy-to-use reagent kits, will initially be employed by researchers and clinical oncologists seeking to group tumors by genomic signature. “Such classifications will make it possible to develop and target therapies more effectively,” Amorese said.

The new, SPET-based technology will also be used by laboratories developing diagnostic tests and by pharmaceutical companies to develop, test and predict the efficacy of specific therapeutics for individual cancer patients. All of the above will   contribute to the realization of precision medicine, Hutt said.

Amorese likened the new SPET method to “a microscope with greater power to detect fusions than has ever before been available.” Now, he said, “you can look for potential fusion events among hundreds of genes known to be associated with tumors just as easily as you can look at a single gene.  Tests that narrowly focus on small subsets of potential fusions can be misleading and fail to take advantage of the power of next gen sequencing.  Those tests are just scratching the surface as it relates to understanding what is happening in the cell.  ” Amorese said.

The complete article, “An Efficient Method for identifying gene fusions by targeted RNA sequencing from fresh frozen and FFPE samples,”  is by  Jonathan A. Scolnick, Michelle Dimon, I-Ching Wang, Stephanie C. Huelga, and Douglas A. Amorese, all of NuGEN Technologies. The article will be available free of charge at 2 pm July 1, 2015 at http://dx.plos.org/10.1371/journal.pone.0128916 http://dx.plos.org/10.1371/journal.pone.0128916 . For an advance copy, please contact Anita Harris, anita.m.harris at harriscom.com.

 

NuGEN Technologies Inc. is a rapidly-growing, privately-held company that provides  innovative products and systems used to prepare biologic samples for targeted genomic analysis.  Founded in 2000 and based in San Carlos, CA, NuGEN has long been at the cutting edge of genomic technology, with accurate, cost-effective reagent kits for even the most challenging sample types.  NuGEN products are used in more than 1000 leading life science institutes and in diagnostic and pharmaceutical  companies in 40 countries.

HarrisCom’s Harris & Pirozzolo speak on book publishing for business

amhimage-FBAnharris | Harris Communications Group
Harris Communication Group  Managing Director Anita M. Harris and colleague Dick Pirozzolo told independent PR  practitioners how  book publishing for business can enhance your reputation and your clients’ –yesterday at the Weston Public Library.
As  published authors and PR professionals,  the pair discussed how books enhance professional prestige and thought leadership, underscore expertise, establish authority, create numerous spin-off media opportunities and generate passive income.
Topics included:
– How to get a publisher to buy your book
– Self-publishing in the internet age
– The value of e-books
– What every winning book proposal must include
– Crowdfunding, pricing your book, and other money matters
– How to market your book
Dick Pirozzolo is the author of three books on homebuilding and two corporate biographies. Anita Harris is the author of Broken Patterns,  and Ithaca Diaries, two nonfiction works that have established her as a forward-looking social and business culture authority.

–Anita M. Harris
Anita Harris is the managing director of the Harris Communications Group,  an award-winning public relations firm specializing in integrated strategic communication, content marketing and thought leadership for clients in healthcare, life sciences, technology, energy and education,  worldwide.  Contact us!

HarrisCom Advisors To Address Data Mining Meetup June 18, 2014

 

The Boston Data Mining Meetup will feature Mark Kon and Eric Morris, both of whom are advisors to the Harris Communications Group.  The talks , to begin at 6:30 pm on Wednesday, June 18, will explore the application of both neural networks and machine learning in the financial markets–followed by networking and refreshments.   For  location or more information–please sign up on line or email info@harriscom.com.

    Professor Mark Kon of Boston University will present: “Some background on machine learning and its uses in financial prediction”Machine learning is still a growing field in both its theoretical aspects and its applications.  It is being applied to such areas as robotics, self-driving cars, and  computational biology/drug discovery.   Its origins lie in artificial neural network theory, which beg

[media-credit standalone=0 id=1 align="alignleft" width="114"]Mark Kon[/media-credit]

Mark Kon

an an evolution in the 90s toward the broader field of machine learning.  The area is based on some simple principles which I will discuss. The first is the  universality of feature vectors, i.e., the possibility of encoding all objects into strings of numbers.  The second is the “geometrization” of learning, i.e., the translation of learning problems into geometrical location tasks, and the third is the so-called kernel trick.  I will explain the basic ideas and give examples of applications in financial and other areas.

  • About the presenter:  

    Mark Kon is a professor of Mathematics and Statistics at Boston University, and is also a faculty member in the Neuroscience and Bioinformatics programs.   His areas of research  have included neural networks, machine learning, computational biology, and quantum computation.   He studied mathematics, physics, and psychology at Cornell, and mathematics at MIT.

    Entrepreneur Eric Morris presents “Introduction to Neural Networks in Financial Market Analysis”

    Neural networks for machine learning have a rich history and recent resurgence in applied problems across a wide range of fields, especially where it is challenging to write rule-based programs. In this talk we will briefly explore the biological foundation of neural networks and why the human brain can be a highly advantageous paradigm from which to construct analytic hypotheses. After an introduction to biological neural networks, we will explore the application of these characteristics to artificial neural networks and their components. Finally, we will use what we have learned to demonstrate a practical application of applying neural networks to financial data to generate a predictive hypothesis.

    About the presenter:

    Eric Morris is consulting out of the Cambridge Innovation Center and working on several projects in the finance and technology space. He recently left the French firm Capgemini where he was a consultant on strategy and technology to Fortune 500 clients. Eric graduated with honors from Cornell University where he earned a double major studying Biology (concentrating in biotechnology and business) and Applied Economics and Management in Cornell’s College of Agriculture and Life Sciences School and Dyson School of Applied Economics and Management respectively.

    –Anita M. Harris

    Anita Harris is managing director of the Harris Communications Group, an award-winning marketing and PR firm based in Kendall Square, Cambridge, MA.  She, in fact, suggested both speakers to Meetup Organizer Sheamus McGovern.

HarrisCom’s Anita Harris to speak on Independent publishing May 14

Anita M. Harris, Managing Director of the Harris Communications Group, will speak on a panel entitled  “BOOK PUBLISHING ON YOUR OWN” on Wednesday, May 14, 2014, in the Lincoln Public Library.  3 Bedford Road, Lincoln, MA.

Authors Susan Coppock, Anita Harris and Rick Wiggin of the Write Stuff will describe their experiences in publishing and marketing their books, which will be available for purchase. Light refreshments will be served.

About the authors
Susan Coppock is the author of Fly Away Home: A Coming of Age Memoir, which describes her unusual childhood and adolescence as the daughter of disengaged parents, continuing through early adulthood until her mother’s death. Susan used a turnkey service from Book Baby to create and distribute her book in electronic form. At 25,000 words, the book is too long for a magazine but too short to interest traditional publishers, an example of how technology has opened up a new market for works of intermediate length called e-singles in industry parlance.

Anita Harris is the author of Broken Patterns: Professional Women and the Quest for a New Feminine Identity, a book first published by Wayne University Press, about the changing role of women in society over time. The original book was out of print, so Anita purchased back the rights, updated the book and published the new edition in both e-book and paperback formats through Cambridge Common Press, her own publishing imprint.

Rick Wiggin is the author of Embattled Farmers: Campaigns and Profiles of Revolutionary Soldiers from Lincoln, Massachusetts, 1775-1783, a history of the revolutionary war focusing on the military service of Lincoln residents during the conflict, including profiles of the 256 documented combatants. The Lincoln Historical Society published Rick’s book in hardback and paperback; it is not available in e-book format.

Directions and parking: http://www.lincolnpl.org/index.php/how-do-i/get-to-library

 

###

Next Page »